Delivery Order SPE2DB20D1100-SPE2DB25FA0K0

Award Date 1/13/25
Potential Completion Date 1/14/25
Potential Value $3.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $3,020.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a delivery order, is for the supply of Restasis 0.05% eye emulsion. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC...
This federal contract award, valued at $5,579.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Restasis 0.05% eye emulsion, a specialty pharmaceutical product. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Restasis 0.05% Eye Emulsion 30s. The $2,853.54 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to provide a comprehensive range of...
This federal contract award, valued at $6,549.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of Restasis 0.05% eye emulsion 30s. The award, valued at $1,976.70, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, worth up to $999,999,999 and running through November 2026. This IDC enables the DLA to procure a comprehensive range of pharmaceutical products...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,938.39 contract is for the delivery of Restasis 0.05% eye emulsion. The contract has a completion date of June 29, 2022 and is a firm fixed-price delivery order. This award is associated with AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Restasis 0.05% eye emulsion. The contract, valued at $3,180.58, is a firm fixed-price delivery order with a completion date of November 26, 2021. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to...
This federal contract award, valued at $10,247.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a completion date of May 19, 2022. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office division, a major pharmaceutical distributor, to provide Restasis 0.05% eye emulsion. The contract has a ceiling value of $24,566.07 and is a firm fixed-price delivery order, without a set-aside designation. Amerisourcebergen holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025,...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,023.80 firm fixed-price delivery order (SPE2DB22FN07L) is for the supply of Restasis 0.05% eye emulsion to support military treatment facilities and federal healthcare programs. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB25FA0K0
    Delivery Order

This federal contract award, valued at $3,877.96, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Restasis 0.05% eye emulsion, a specialty pharmaceutical product.

The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which has a potential value of $999,999,999 and runs through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

In addition to the DLA contract, Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 5/21/25, 9:58 AM